期刊文献+

低出血倾向、低免疫原性葡激酶mSAK(K130T,K135R)的表达、纯化与活性测定

Constuction, Over-expression, Purification and Activity Analysis of mSAK (K130T,K135R) with Reduced Immunogenicity and Lower Bleeding Tendency
下载PDF
导出
摘要 为了有效降低葡激酶应用的副作用,构建低出血倾向、低免疫原性葡激酶突变体,高效表达纯化后进行活性鉴定,以野生型重组葡激酶基因为模板,PCR法引入突变位点(K130T,K135R),并将该片段克隆测序鉴定后,克隆至表达载体pBV220,构建低免疫原性葡激酶突变体.表达后的蛋白用Q-Sepharose FF柱与Sephacryl S-200进行纯化,纤维蛋白溶圈法进行活性测定,体外抗体中和试验与豚鼠免疫试验测定突变体蛋白的免疫原性,同时进行动物体内出血倾向观察.测序结果表明,相应位点获得突变,无非特异性突变,将突变后的片段连接pBV220导入大肠杆菌热激诱导获得了高效表达,表达产物占菌体总蛋白的40%~50%.产物主要以可溶性形式存在,经两步纯化后的蛋白的纯度可达98%以上.活性测定试验表明,该突变体的活性较野生型葡激酶稍低,体外中和抗体试验和豚鼠免疫试验证明免疫原性大为下降,豚鼠的皮肤出血以及肺部病理切片均显示该突变体蛋白引起的出血倾向明显降低. To construct mSAK mutant with reduced immunogenicity and lower bleeding tendency, and identify its biological activity after purification, mSAK (K130T, K135R) gene fragment was amplified by PCR and inserted into the prokaryotic expression vector pBV220 with PRPL promoters after confirmed by DNA sequencing. The expression plasmid pBV220-mSAK (K130T, K135R) was constructed, and then was transformed into E. coil DHSα. After temperature induction, the mutant staphylokinase was over-expressed and much of the protein was in the supernate of lysates, which was about 40% ~ 50% of total protein in the host cells. The protein was isolated and purified in Q-Sepharose FF and Sephacryl S-200 HR, high purity protein was obtained with purity 98% . The thrombolysis activity of the mSAK protein was 8.77 × 10^4 U/mg by fibrin plate assay, which was slightly lower than that of wild type, and antiserum titers in guinea pigs were much lower than those of wild-type SAK with ELISA assay. Its immunogenicity, which was determined by both antibody neutralizing assay in vitro and guinea pig in vivo, was sharply reduced comparing to that of wild-type staphylokinase. Meanwhile, all guinea pigs in wt-SAK immunogenicity assay have body surface bleeding while the bleeding was not observed in mSAK group, and this was confirmed by the lung pathological section. These results provided the basis for further research of mSAK with lower bleeding tendency.
出处 《中国生物化学与分子生物学报》 CAS CSCD 北大核心 2005年第5期610-615,共6页 Chinese Journal of Biochemistry and Molecular Biology
基金 北京市自然科学基金(No.7992030) 军事医学科学院新药开发基金(No.200108041)~~
关键词 葡激酶 免疫原性 低出血倾向 staphylokinase, immunogenicity, lower bleeding tendency
  • 相关文献

参考文献10

  • 1Collen D, Van de Werf F. Coronary thrombolysis with recombinantstaphylokinase in patients with evolving myocardial infarction. Circulation, 1993,87(6): 1850 ~ 1853. 被引量:1
  • 2Schlott B, Hartmann M, Guhrs K H, Birch-Hirschfeld E, Pohl H D, Vanderschueren S, Van de Werf F, Michoel A, Collen D, Behnke D. High yield production and purification of recombinant staphylokinase for thrombolytic therapy. Biotechnology, 1994,12(2): 185 ~ 189. 被引量:1
  • 3Vanderschueren S, Barrios L, Kerdsinchai P, Van den Heuvel P, Hermans L, Vrolix M, De Man F, Benit E, Muyldermans L, Collen D, Van de Werf F. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STAR Trial Group. Circulation, 1995, 92(8): 2044 ~ 2049. 被引量:1
  • 4Vanderschueren S, Stockx L, Wilms G, Lacroix H, Verhaeghe R, Vermylen J, Collen D. Thrombolytic therapy of peripheral arterial occlusion with recombinant staphylokinase. Circulation, 1995,92(8): 2050 ~ 2057. 被引量:1
  • 5Jenne S, Brepoels K, Collen D, Jespers L. High resolution mapping of the B cell epitopes of staphylokinase in humans using negative selection of a phage-displayed antigen library. J Immunol, 1998, 161(6) :3161 ~ 3168. 被引量:1
  • 6宋钢,莫炜,宋后燕.低免疫原性的新型葡激酶ΔNMSak在大肠杆菌中的高效表达和分离纯化[J].中国生物化学与分子生物学报,2000,16(6):727-731. 被引量:2
  • 7Schlott B, Hartmann M, Guhrs K H, Birch-Hirschfeld E, Gase A, Vettermann S, Collen D, Lijnen H R. Functional properties of recombinant staphylokinase variants obtained by site-specific mutagenesis of methionine-26. Biochim Biophys Acta, 1994,1204 (2): 235 ~ 242. 被引量:1
  • 8Gase A, Hartmann M, Guhrs K H, Rocker A, Collen D, Behnke D, Schlott B. Functional significance of NH2- and COOH-terminal regions of staphylokinase in plasminogen activation. Thromb Haemost, 1996,76 (5) :755 ~ 760. 被引量:1
  • 9Moreadith R W, Collen D. Clinical development of PEGylated recombinant staphylokinase (PEG-Sak) for bolus thrombolytic treatment of patients with acute myocardial infarction. Adv Drug Deliv Rev, 2003,55(10): 1337 ~ 1345. 被引量:1
  • 10Vanwetswinkel S, Plaisance S, Zhi-Yong Z, Vanlinthout I, BrepoelsK, Lasters I, Collen D, Jespers L. Pharmacokinetic and thrombolytic properties of cysteine-linked polyethylene glycol derivatives of staphylokinase. Blood, 2000,95(3) :936 ~ 94221(5):616~621. 被引量:1

二级参考文献3

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部